PF-06804103 Dose Escalation in HER2 Positive Solid Tumors

• Breast Neoplasms
• Stomach Neoplasms
• Esophagogastric Junction Neoplasm
• Carcinoma, Non-small-cell Lung

• Drug: PF-06804103
  
  Dose Escalation Phase - Part 1
• Drug: PF-06804103
  
  Dose Expansion Phase - Part 2

Inclusion Criteria:

• HER2 positive breast cancer or gastric cancer that is resistant to standard therapy or for which no standard therapy is available
• Performance status of 0 or 1
• Adequate bone marrow, kidney and liver function

Exclusion Criteria:

• Known CNS disease including, but not limited to, metastases
• History of exposure to certain cumulative doses of anthracyclines
• Grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy
• Active and clinically significant bacterial, fungal, or viral infection
• Abnormal cardiac function defined by a LVEF <50% by ECHO or MUGA
• Patients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseases